Huminsulin 30/70: Complete Product Overview

Huminsulin 30/70 – Premixed Human Insulin for Effective Diabetes Management

Huminsulin 30/70 is a premixed human insulin formulation designed to help manage blood glucose levels in individuals with diabetes mellitus. It combines short-acting and intermediate-acting insulin in a fixed proportion, providing both mealtime blood sugar control and longer-lasting insulin coverage.

It is commonly prescribed for people with type 1 or type 2 diabetes who require insulin therapy. When used according to medical advice, alongside a balanced diet, regular physical activity, and blood glucose monitoring, Huminsulin 30/70 helps maintain better glycemic control and reduce the risk of diabetes-related complications.

1. Composition and Formulation

Huminsulin 30/70 contains two types of human insulin in a carefully formulated fixed ratio:

• 30% Regular Human Insulin (Short-Acting): Helps control the rise in blood glucose levels following meals. It generally begins working approximately 30 minutes after administration and provides insulin coverage during the post-meal period.

• 70% NPH Human Insulin (Intermediate-Acting): Also known as isophane insulin, it is absorbed more gradually and helps regulate blood glucose levels between meals and during overnight periods.

The combination provides two complementary insulin actions in a single injection, potentially reducing the need for separate injections of regular and intermediate-acting insulin.

Huminsulin 30/70 is available in different strengths and presentations depending on the market, including vials and cartridges. Patients must always verify the insulin concentration and use compatible injection equipment.

2. Indications and Therapeutic Uses

Huminsulin 30/70 is indicated for the treatment of diabetes mellitus in patients who require insulin to maintain appropriate blood glucose control.

Primary Therapeutic Uses:

• Type 1 Diabetes Mellitus: May be prescribed as part of an individualized insulin treatment regimen for patients who require insulin replacement.

• Type 2 Diabetes Mellitus: Helps control blood glucose when lifestyle changes, oral antidiabetic medications, or other treatments are insufficient.

• Blood Glucose Regulation: Helps manage elevated blood sugar levels before and after meals.

• Long-Term Diabetes Management: Supports sustained glucose control when used consistently under medical supervision.

• Prevention of Diabetes-Related Complications: Improved glucose management can help lower the long-term risk of complications affecting the kidneys, eyes, nerves, and cardiovascular system.

Huminsulin 30/70 should only be used when prescribed by a qualified healthcare professional.

3. Mechanism of Action: How Huminsulin 30/70 Works

Huminsulin 30/70 works by replacing or supplementing the insulin naturally produced by the pancreas. Insulin is an essential hormone responsible for regulating blood glucose levels and enabling body cells to absorb glucose for energy.

Short-Acting Regular Insulin (30%):

• Generally begins working approximately 30 minutes after injection.

• Helps control increases in blood glucose associated with food consumption.

• Commonly reaches peak activity within approximately 2–4 hours, although individual responses vary.

• Supports the movement of glucose from the bloodstream into muscle and fat cells.

Intermediate-Acting NPH Insulin (70%):

• Provides a more gradual and prolonged glucose-lowering effect.

• Helps maintain blood glucose control between meals.

• Contributes to insulin coverage during daytime and overnight periods.

• Its activity varies with dose, injection site, and individual metabolism.

The combined formulation commonly begins acting within approximately 30 minutes, with glucose-lowering activity that may continue for around 14–24 hours. The actual onset, peak, and duration vary considerably between individuals.

4. Dosage and Administration

The dosage of Huminsulin 30/70 must be individualized according to the patient's medical condition, blood glucose readings, dietary habits, physical activity, and treatment requirements.

Administration Guidelines:

• Route of Administration: Administered by subcutaneous injection (under the skin).

• Injection Sites: Common injection areas include the abdomen, thighs, upper arms, and buttocks.

• Injection Frequency: Often prescribed once or twice daily, depending on the individual's treatment plan.

• Dose Adjustment: Changes in dosage should be made only under medical supervision.

• Injection Site Rotation: Injection sites should be rotated regularly to reduce the risk of lipodystrophy and localized tissue changes.

• Proper Mixing: Because it contains an insulin suspension, the product must be gently resuspended according to its specific manufacturer's instructions before administration.

Huminsulin 30/70 must not be administered intravenously or through an insulin pump. Patients should use the prescribed insulin strength and appropriate delivery device.

5. Blood Glucose Monitoring

Regular blood glucose monitoring is an essential component of successful insulin therapy. It helps evaluate treatment effectiveness, identify glucose fluctuations, and reduce the risk of hypoglycemia or hyperglycemia.

Recommended Monitoring Practices:

• Check blood glucose as instructed by a healthcare provider.

• Monitor fasting and post-meal glucose levels when recommended.

• Record readings to identify trends and changes over time.

• Monitor blood glucose more frequently during illness, changes in physical activity, or adjustments to the treatment regimen.

• Attend regular medical appointments for HbA1c testing and diabetes assessment.

• Watch for symptoms of low or high blood glucose and seek medical guidance when necessary.

Continuous glucose monitoring systems may also be recommended for selected patients.

6. Timing of Insulin Administration

Correct administration timing is important for achieving appropriate blood glucose control and minimizing treatment-related complications.

Huminsulin 30/70 is generally administered approximately 30–45 minutes before a meal, as directed by the prescribing healthcare professional and the specific product instructions.

Important Timing Considerations:

• Maintain consistent injection and meal schedules.

• Avoid skipping or significantly delaying meals after administering insulin.

• Follow the prescribed injection frequency and timing.

• Monitor blood glucose when meal schedules or daily routines change.

• Never take an additional dose to compensate for a missed injection without medical advice.

Because Huminsulin 30/70 contains regular human insulin, its mealtime timing differs from that of certain rapid-acting insulin analogues.

7. Individualized Diabetes Treatment

Every patient with diabetes has different insulin requirements. Therefore, Huminsulin 30/70 therapy must be tailored to individual health conditions and daily routines.

Factors Affecting Insulin Requirements:

• Age and Body Weight: Insulin needs may differ depending on age, body composition, and metabolic requirements.

• Dietary Habits: Meal timing, carbohydrate consumption, and eating patterns influence blood glucose levels.

• Physical Activity: Exercise can increase insulin sensitivity and affect glucose requirements.

• Kidney and Liver Function: Impaired kidney or liver function may change insulin requirements and increase the risk of hypoglycemia.

• Illness and Stress: Infection, fever, surgery, and emotional or physical stress may affect blood glucose control.

• Other Medications: Certain medicines can increase or decrease the glucose-lowering effects of insulin.

Patients should consult their healthcare provider before changing their insulin dosage, treatment schedule, or medication regimen.

8. Potential Side Effects

Like other insulin products, Huminsulin 30/70 may cause side effects. Their frequency and severity vary depending on individual sensitivity, dosage, and treatment conditions.

Common Side Effects:

• Hypoglycemia: Low blood sugar is one of the most important potential side effects. Symptoms may include sweating, shakiness, dizziness, hunger, headache, confusion, and a rapid heartbeat.

• Injection Site Reactions: Redness, mild swelling, itching, or discomfort may occur at injection sites.

• Weight Gain: Some patients may experience weight gain after starting insulin therapy.

• Lipodystrophy: Repeated injections into the same area may cause changes in the fatty tissue under the skin.

• Localized Skin Reactions: Temporary irritation or discomfort may occur after injection.

Less Common but Serious Side Effects:

• Severe hypoglycemia, potentially causing seizures or loss of consciousness.

• Serious allergic reactions, including difficulty breathing, generalized rash, or swelling.

• Hypokalemia (low potassium levels), particularly in susceptible patients.

Patients experiencing severe symptoms should seek immediate medical attention.

9. Safety Precautions and Storage Instructions

Proper handling and safe administration are necessary to maintain insulin effectiveness and minimize potential risks.

Important Safety Precautions:

• Use Huminsulin 30/70 only with a valid prescription and professional medical guidance.

• Do not use the insulin during an episode of hypoglycemia.

• Do not independently increase, decrease, or discontinue the prescribed dosage.

• Confirm the correct insulin type and strength before every injection.

• Do not share insulin pens, cartridges, syringes, or needles with another person.

• Avoid injecting into areas with lumps, thickened skin, or damaged tissue.

• Discuss pregnancy, breastfeeding, kidney disease, liver disease, and other medical conditions with a healthcare provider.

• Consult a healthcare professional before combining insulin with other medications that may affect blood glucose.

Storage and Handling:

• Store unopened insulin in a refrigerator at 2°C–8°C, according to the product labeling.

• Do not freeze insulin or use insulin that has been frozen.

• Protect it from excessive heat and direct sunlight.

• Follow the specific product instructions for storage after opening, including the permitted temperature and use period.

• After proper mixing, the suspension should appear uniformly cloudy or milky. Do not use it if abnormal clumps or particles remain or if the product appears damaged.

Always consult the packaging and manufacturer's leaflet for the exact storage and handling requirements of the supplied presentation.

10. Role in Comprehensive Diabetes Management

Huminsulin 30/70 plays an important role in managing diabetes by providing a combination of mealtime and intermediate-duration insulin coverage.

When used appropriately, it may help patients achieve more consistent blood glucose control and support long-term diabetes management.

Key Benefits:

• Combines short-acting and intermediate-acting human insulin in one formulation.

• Helps manage blood glucose fluctuations associated with meals.

• Provides extended insulin activity between meals.

• May simplify treatment for patients prescribed a premixed insulin regimen.

• Supports improved glycemic control when combined with consistent monitoring.

• Can contribute to reducing the ris